The first question you’re asking yourself is,

“Why is the DEA involved in a biotech stock?"

company to process a massive amount of Cannabis -- more specifically the cannabinoids -- in order to manufacture a medicine delivery system that is 100% patented, safe, and actually solves the biggest problem that medical marijuana is facing.

Yes, the DEA has fully vetting ONE company and their unique process and has given them the stamp of approval to develop their new cannabinoids delivery system.

It’s the DELIVERY SYSTEM That Has Investors’ Attention

In 2015 the researchers at Vitality BioPharma (VBIO) discovered a unique and patented way to bind a plant’s natural sugars (called glycosides) with molecules from other plants.

With Cannabis being all the rage, their research team went to work and were able to bond glycosides to cannabinoids, the chemical compounds found in Cannabis.

What they discovered was a new class of drugs they dubbed “cannabosides.” These revolutionary compounds overcome one of the main obstacles to using Cannabis compounds to fight pain and disease: getting HIGH. This is an incredible breakthrough.

While there are literally hundreds of laboratory tests and clinical trials showing that cannabinoids have powerful medicinal properties, these potent natural healing compounds have one significant drawback to FDA and DEA approval...everyone gets high.

You see, an effective dosage of cannabinoids often makes patients ‘under the influence’ which adversely affects patients’ functions more than the medical issue that the cannabinoids often solves.

Enter VITALITY BIOPHARMA and their new delivery system

effects kick in, causing them to discontinue treatment. (This is exactly what happened in a recent clinical trial conducted by GW Pharmaceuticals, one of the few other companies conducting Cannabis-based research.)

The new class of Cannabis-based drugs developed by Vitality BioPharma (VBIO) overcomes the BIGGEST problem patients deal with.

These revolutionary drugs work by allowing cannabinoids to “ride along” with stevia molecules and travel undigested through the body until they’re released at specific targeted sites. Because the cannabinoids don’t enter the bloodstream as they would if they were ingested without being bonded to a glycoside, there are no psychoactive side effects.

The patient receives a dose high enough to provide therapeutic results, but he or she doesn’t get “high” or “stoned” in the process.

Vitality BioPharma has harnessed the healing power of Cannabis, without the psychoactive side effects, by combining cannabinoids with glycosides from the stevia plant.

One Company Disrupting a $69,300,000,000 Market

Countless hours of research has been done on the healing effects of cannabinoids:

Use of Cannabinoids for Spasticity and Pain Management in MS (1)

The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain​ (2)

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic (3)

But what they all come to the same conclusion:

In fact, all those industries have a combined annual market value of 69.3 BILLION dollars...and VBIO is the only stock poised to make a significant mathematical dent...

LET’S TAKE A LOOK AT THE HARD NUMBERS OF THE LUCRATIVE MARKET THAT VITALITY IS ABOUT TO CHANGE:

Vitality Focuses on GUT HEALTH

According to the Centers for Disease Control and Prevention, as of 2015 an estimated 3 million U.S. adults reported being diagnosed with inflammatory bowel diseases (IBD), either Crohn’s disease or ulcerative colitis. (4)

And a recent medical journal article warned that “IBD is increasing worldwide and has become a global emergence disease.” (5)

Some IBD patients spend their entire life on medications that do little to ease their pain, much less cure the disease. The truly unlucky ones (up to 75% of patients) are forced to undergo surgeries, including colectomies and colostomies.

Unfortunately, that treatment consists of taking medications that do little to stop the pain, much less cure the underlying disease. And the cost of treatment is astronomical. Patients currently spend a mind-boggling $8.5 billion on IBD drugs each year. And that’s forecast to grow to $9.5 billion by 2020. (6)

Ending Superbug Infections

Vitality BioPharma (VBIO) also has their drug “VXB-210” in studies for the treatment of so-called “superbug” infections caused by an extremely nasty bacterium called Clostridium difficile (klos-TRID-e-um dif-uh-SEEL). C. difficile is both extremely virulent and extremely difficult to kill. It affects an estimated half million Americans each year, causing symptoms ranging from diarrhea to life-threatening inflammation of the colon. (7)

In a press release dated May 10, 2017, VBIO announced that it had filed for patent protection on the use of one of its cannabosides (presumably VXB-210) for the treatment of infections caused by Clostridium difficile and other ‘superbug’ pathogens.

Globally Vitality BioPharma is poised to quickly take market share out of that industry!

Attacking Colon Cancer Cells

The National Institute of Health estimates that treatment costs will reach $17.4 billion within the next two years. (10) 

Again, securing just 10% of this market, would provide the company with $1.7 billion of annual revenue.

The List Continues to GROW

As of publication, Vitality BioPharma (VBIO) has identified and obtained protection for almost 200 cannabinoid/glycoside combinations that appear to have medicinal value. Only about 20 of those, thus far, have been used to create actual drugs.

There’s so much research in the pipeline that the amount of drugs that VBIO could bring to market may be in the HUNDREDS.

The Team Leading The Movement

In my recently published ebook, I list several key factors that helped medical stocks explode...one of the biggest was the TEAM behind the company. The leadership, research, and depth are factors about which investors take note. Vitality BioPharma’s team (below) have this “it” factor.

10 Keys For Massive Success (History Lesson)

In my 25 years of trading and research I’ve discovered that there are 10 KEYS to massive stock success...short term and long term. These I cover in my ebook​, but suffice it to say that when they ALL align then the market truly has the potential to deliver a trading opportunity like none other.

UPDATE: VBIO has hit ALL 10 KEYS...

VBIO has met both of these challenges and changed the whole dynamic of the industry by unlocking the medicinal potential of CBD, while eliminating all the negative side effects.

Having all 10 of these key factors locks-in mega profit potential for investors. VB100 & VB210 has been shown to treat a multitude of illnesses and has shown to be a safe alternative and more effective than other treatments currently available. They are leading the industry developing new compounds and protecting their IP. Knowing all this takes research and industrial knowledge that takes time to consume and mentally digest. However, one thing an investor cannot control is time. When is the best time to invest in a biopharma company? What has happened over time?

This is what makes VBIO’s cannabinoid pharmaceuticals unique and sets them apart from every other CBD pharma on the market or currently undergoing clinical trials. VBIO holds the patents to their own compounds and has continued to show increased safety and efficacy upon entering phase II trials with VB210 and VB100 in 2018.

And as the market continues to change we will see more and more Cannabis products and services try to make a dent in the medical niche...the issue they will face is timing.

First and BEST to market often dominate.

The rest are just picking up scraps.

Don’t forget to follow the 10 Keys For Massive Success, laid out in my new ebook, that will help you discover for yourself how to make wise investments in the pharma/biotech niche.